The world will be moving forward with immeasurable effects from the COVID-19 pandemic, as will the pharmaceutical industry. Fully understanding the impact that the pandemic will have on pharma will take years; however, there are future…
Through an intense U.S. election season, there is one issue that patrons of the right and left agreed on: The cost of prescription drugs is viewed as unfair and unsustainable. With President Joe Biden in office,…
As pharma companies race to keep up with today’s market, your brand’s team can’t afford to be out of sync. Yet inefficiencies and miscommunications are common throughout the commercialization process — wasting valuable resources, creating confusion among key stakeholders and slowing…
The Centers for Medicare and Medicaid Services (CMS) on January 12 finalized its proposal of Medicare Coverage of Innovative Technology (MCIT), an additional pathway of coverage for breakthrough-designated medical devices, providing timelines and clarifying definitions of…
From commercializing high-science therapies to empowering a data-driven patient experience (in the midst of a global pandemic!), we’ve learned that the life sciences industry requires agility, speed and scale. How will 2020 experiences set the emerging…
As we begin 2021 and vaccines roll out across the globe, it seems that the world is hopeful and eager to move forward from 2020. The COVID-19 pandemic impacted almost every aspect of our lives, wreaking havoc on numerous industries and forcing global companies to re-evaluate their…
The new year began with a light of hope ignited by the long-awaited COVID-19 vaccine. However, a vaccine is only the first step in fighting the pandemic. Healthcare professionals and drug manufacturers must continue to apply…
Data Is Transforming the Landscape In a special feature on Digital Influencers, PharmaVOICE Editor Taren Grom sat down with Brigham Hyde, President, Data & Analytics to discuss how data is transforming the life sciences landscape as…
Pharmaceutical representatives have always been a welcomed resource and consistent office visitor for healthcare providers (HCPs). Today, in a world operating largely virtually, pharma reps are re-strategizing HCP engagement in the same way providers are rethinking…
High-stake or complex therapies, such as cell and gene therapies, immunotherapies and RNA interference (RNAi), have the potential to change the course of treatment for cancer patients and patients with rare diseases. But first, pharma companies must work with providers to navigate patient access complications…